For important risk and disclaimer information, Click here.

Industry

Technology

Company Type

Medical Devices, Tech, 3D, Artificial Intelligence

Size

+/-$50 Million

Investment Type

Debt/Equity

For additional information, please contact:
Rebecca Lacy | Managing Director
(573) 880-2974

Executive Summary

  • AI-driven 360° imaging transforming skin screening & aesthetics in a $44B+ market

 

  • Only solution with real-time AI lesion detection plus automated 360° imaging, backed by 21 patents

 

  • Revenue-generating with signed contracts and strong pipeline awaiting funding for fulfillment

 

  • Clinically validated: Endorsed by practitioners with proven impact in pilot programs

 

  • Raising $50M (Debt/Equity) to scale commercialization, fulfill contracts, and advance AI technology

Skin Cancer is a Growing Public Health Crisis

  • Skin cancer is more prevalent than all other cancers combined

 

  • 1 in 5 Americans will develop skin cancer by age 70

 

  • More than 9,500 people are diagnosed in the U.S. every day and more than two people die every hour

 

  • Invasive melanoma cases have surged 46% in the past decade (2015-2025)

 

  • Melanoma early detection = 99% survival vs. only 35% for late-stage diagnosis

The Need for a More Advanced Approach

Gaps in current methods which will be addressed by improved technology

  • Most diagnosis still relies on subjective visual assessment (SPLs & Ugly Duckling Method)

 

  • Dermoscopy is slow, expensive, and requires highly trained specialists

 

  • Near-field imaging lacks the full-body context needed for accurate comparison

 

  • High misdiagnosis & false positive rates increase patient stress & costs

 

  • Primary care providers lack the tools for accurate triage, which can result in delayed referrals

The Solution: oVio 360° AI Imaging

How oVio Solves These Challenges:

  • AI-Powered Precision (dermAId™): Detects lesions 10X more accurately than the human eye

 

  • First-of-Its-Kind 360° Imaging: Fully automated, real-time AI mapping, eliminating manual errors

 

  • Seamless EMR Integration: Plug-and-play Open API ensures instant compatibility with hospitals & clinics

 

  • AI That Gets Smarter: Continuous learning SaaS model improves diagnostics with every scan

 

  • AI automation reduces manual workload, standardizes diagnostics, and enhances long-term SaaS revenue

Competitive Advantage & Differentiation

How oVio Solves These Challenges:

  • AI-Powered Precision (dermAId™): Detects lesions 10X more accurately than the human eye

 

  • First-of-Its-Kind 360° Imaging: Fully automated, real-time AI mapping, eliminating manual errors

 

  • Seamless EMR Integration: Plug-and-play Open API ensures instant compatibility with hospitals & clinics

 

  • AI That Gets Smarter: Continuous learning SaaS model improves diagnostics with every scan

 

  • AI automation reduces manual workload, standardizes diagnostics, and enhances long-term SaaS revenue

oVio’s Proven Leadership Team

oVio’s leadership team brings deep expertise in corporate finance, operations, and healthcare AI. With a proven track record of scaling businesses, securing strategic partnerships, and driving commercialization, they are uniquely positioned to lead oVio’s growth in AI-powered skin diagnostics. Backed by world-class medical and AI advisors, oVio is set to transform the industry.

George Rebensdorf – Co-Founder and Chief Executive Officer

Over 39 years of executive management and advisory focused on corporate finance, merger and acquisition transactions. Currently, CEO of oVio Technologies (co-founded in 2015); Managing Partner, Implicit Care (predecessor of oVio Technologies); and President, The Rebensdorf Group (TRGI), a boutique investment banking and corporate finance advisory firm. Previously served as Managing Partner at E/W Capital, a mid-market investment advisory firm; Senior Vice President at Midcom Communications; and General Partner at Telenational Communications (TNCL). Authored numerous publications. JD, Creighton University School of Law. BA (magna cum laude) English, Arizona State University.

Theodore Edmund Gagliano – Co-Founder and Director

Over 32 years of strategic management, planning, operations and talent recruitment within the entertainment industry. Currently, Director at oVio Technologies; and Feature Film/TV Consultant, 20th Century Fox. Previously served as President, Post-Production at 20th Century Fox. Life-Time Achievement Award, Hollywood Post-Production Alliance. Board Member, Princeton University Triangle Club; and Board of Advisors Member, UCLA Department of Neurosurgery. Honorary PhD, Anglica Ruskin University (UK). BA in Comparative Literature, Princeton University.

Brian A. Middleton – Chief Financial Officer

Over 12 years of experience in global financial management and oversight within the infrastructure and logistics sector. Subject matter expert (SME) and Primary Point of Contact (POC) for profitability reporting at FedEx Express –  oversees the global air and road network and manages over $1 billion in expense allocation each month. Awarded Key to the City of Memphis in 2014. Member of the Project Management Institute. Project Management Professional (PMP) certification. MBA Johns Hopkins University Carey Business School.

Specific Risks

Financial models and other supporting information regarding historical data, hypothetical target returns, contextual analysis, and other pertinent matters will be made available to prospective investors upon request. There is no guarantee of success, and there is a potential for loss of your investment.

 

Risks related to early-stage company

  • Limited financial history, limited assets, and cash flows

Risks related to liquidity

  • Insufficient capital to support operations and growth; oVio Technologies may need additional financing for development, marketing and growth

Risks related to the economy

  • Decline in economic demand could negatively impact prices and demand, and prevent expected returns on investment 

Risks related to technology

  • Infringement on oVio Technologies’ patents; alternative new technology could be developed and preferred in the market

Risks related to competition

  • Existing and/or new entrants, some with deep pockets and global operations, could develop and/or expand to compete in oVio Technologies markets

Risks related to key person

  • Lightly-staffed and expertise is concentrated in a few key executives; expansion will require finding experienced personnel to fill open positions

Risks related to operations

  • Higher than expected operating costs, unexpected equipment / supply chain bottlenecks

Risks related to the regulation and taxes

  • New legislation and/or change in regulation, taxes could negatively impact operations and/or costs

Risks related to investment

  • Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment
Learn More About oVio Technologies Inc.

Thank you for your interest in oVio Technologies Inc.

Please fill out your information and we will contact you shortly with more information on this opportunity.

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

CONTACT US

Hi. We're not around right now. But you can send us an email and we'll get back to you, asap.

Thanks, Ken

Ken Margolis | Managing Partner Castle Placement, LLC
1460 Broadway Street, Rte 400
New York, New York 10036
(212) 418-1188 | C: (516) 712-7784
kmargolis@castleplacement.com

Sending